Nicole Laslett, DO
Hematology & Oncology · Newark, DENPI 1154716371
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,168 of the $1,481 with a category attached, or 78.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,013 and has fallen 87.7% since, to $125 in 2023.
Across 73 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$275
- E.r. Squibb & Sons, L.L.C.$224
- AstraZeneca$181
- Lilly USA, LLC$176
- Novartis$140
- Bristol Myers Squibb$92
- plus $393 from 13 others
Across 1 payment — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
What the payments were for
- Food & beverage$1,16879%
- Education$31421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 7 | $275 |
| E.r. Squibb & Sons, L.L.C. | 14 | $224 |
| AstraZeneca | 6 | $181 |
| Lilly USA, LLC | 13 | $176 |
| Novartis | 6 | $140 |
| Bristol Myers Squibb | 5 | $92 |
| Pfizer | 5 | $69 |
| Stemline Therapeutics Inc. | 3 | $63 |
| Incyte Corporation | 4 | $59 |
| Daiichi Sankyo Inc. | 1 | $35 |
| Dova Pharmaceuticals | 1 | $24 |
| Genentech USA, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Amgen | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $19 |
| Gilead | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
How this compares
$1,481 in reported general payments places this provider in the 65th percentile of 26 hematology & oncology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 18 | $23,118 |
| EliquisApixaban | 27 | $17,345 |
| Anastrozole | 281 | $8,726 |
| Exemestane | 17 | $1,529 |
| Letrozole | 69 | $1,509 |
| Tamoxifen Citrate | 37 | $671 |
| Raloxifene Hcl | 11 | $475 |
| Ondansetron OdtOndansetron | 17 | $294 |
| Oxycodone Hcl | 11 | $290 |
| Ondansetron Hcl | 16 | $278 |
| Dexamethasone | 12 | $131 |
| Omeprazole | 12 | $117 |
| Escitalopram Oxalate | 23 | $98 |
| Prochlorperazine Maleate | 11 | $90 |
| Prednisone | 15 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $69 | $17,34527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 26 hematology & oncology providers in Delaware.
Other hematology & oncology in Newark
- Dhaval ShahNewark$10K
- Jason PalopoliNewark$4K
- Jamal MislehNewark$2K
- Evan LapinskyNewark$2K
- Kathiresan SuppiahNewark$2K
- Sujung ParkNewark$1K
- Ramya VaradarajanNewark$901
- Palak ShahNewark$750
- Amy McGheeNewark$646
- Philip MargiottaNewark$521
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.